The global deep brain stimulation (DBS) device market is projected to see steady growth through 2035, driven by increasing prevalence of neurological disorders and advancements in device technology. Key players like Medtronic, Boston Scientific, NeuroPace, and Aleva Neurotherapeutics are investing in innovation, targeting Parkinson’s disease, essential tremor, and treatment-resistant depression. The report highlights how strategic mergers, FDA clearances, and emerging clinical applications are shaping this high-impact segment of interventional psychiatry.